Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3032434rdf:typepubmed:Citationlld:pubmed
pubmed-article:3032434lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3032434lifeskim:mentionsumls-concept:C1516238lld:lifeskim
pubmed-article:3032434lifeskim:mentionsumls-concept:C0149925lld:lifeskim
pubmed-article:3032434lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:3032434lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:3032434lifeskim:mentionsumls-concept:C0205231lld:lifeskim
pubmed-article:3032434pubmed:issue5lld:pubmed
pubmed-article:3032434pubmed:dateCreated1987-6-9lld:pubmed
pubmed-article:3032434pubmed:abstractTextTwenty-one previously untreated patients with extensive small cell lung cancer were treated with etoposide, 400 mg/m2/day for 3 consecutive days. Myelosuppression was severe, with a treatment-related death rate of 28%. Five partial responses were achieved. High-dose etoposide as given in this study produced unacceptable toxicity and no complete responses.lld:pubmed
pubmed-article:3032434pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3032434pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3032434pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3032434pubmed:languageenglld:pubmed
pubmed-article:3032434pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3032434pubmed:citationSubsetIMlld:pubmed
pubmed-article:3032434pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3032434pubmed:statusMEDLINElld:pubmed
pubmed-article:3032434pubmed:monthMaylld:pubmed
pubmed-article:3032434pubmed:issn0361-5960lld:pubmed
pubmed-article:3032434pubmed:authorpubmed-author:GreenM RMRlld:pubmed
pubmed-article:3032434pubmed:authorpubmed-author:PerryM CMClld:pubmed
pubmed-article:3032434pubmed:authorpubmed-author:PropertK JKJlld:pubmed
pubmed-article:3032434pubmed:authorpubmed-author:LuikartS DSDlld:pubmed
pubmed-article:3032434pubmed:authorpubmed-author:ModeasC RCRlld:pubmed
pubmed-article:3032434pubmed:issnTypePrintlld:pubmed
pubmed-article:3032434pubmed:volume71lld:pubmed
pubmed-article:3032434pubmed:ownerNLMlld:pubmed
pubmed-article:3032434pubmed:authorsCompleteYlld:pubmed
pubmed-article:3032434pubmed:pagination533-4lld:pubmed
pubmed-article:3032434pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:meshHeadingpubmed-meshheading:3032434-...lld:pubmed
pubmed-article:3032434pubmed:year1987lld:pubmed
pubmed-article:3032434pubmed:articleTitleHigh-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study.lld:pubmed
pubmed-article:3032434pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3032434pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3032434pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed